Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Deals

Shanghai Pharmaceuticals and Sanofi Broaden Collaboration to Include Nationwide Disease Management

Fineline Cube Jan 3, 2024

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) , a leading pharmaceutical company based in China,...

Company Legal / IP

Servier Faces $475 Million Penalty Over Banned Antidiabetic Drug Mediator in France

Fineline Cube Jan 2, 2024

French pharmaceutical company Servier has been ordered by a French court to pay €430.6 million...

Company Legal / IP

J&J Shareholders Cleared to Sue Over Hidden Asbestos Risks in Talc Products

Fineline Cube Jan 2, 2024

A US federal court has granted permission for certain Johnson & Johnson (J&J; NYSE: JNJ)...

Policy / Regulatory

China’s CDE Releases Guidelines for CGT Clinical Trials Communication

Fineline Cube Jan 2, 2024

The Center for Drug Evaluation (CDE) in China has released the “Technical Guiding Principles for...

Policy / Regulatory

China’s NHC Unveils Plan to Conserve Drug Resources and Reduce Waste

Fineline Cube Jan 2, 2024

The National Health Commission (NHC) of China, in collaboration with four other bureaus, has released...

Policy / Regulatory

China’s NHC Unveils Guidelines to Fortify County-Level Medical Communities

Fineline Cube Jan 2, 2024

The National Health Commission (NHC) of China, in conjunction with nine other ministries, has issued...

Company Deals

Roche to Expand Diagnostics Portfolio with Acquisition of LumiraDx Technology

Fineline Cube Jan 2, 2024

Pharmaceutical giant Roche (SWX: ROG), based in Switzerland, has announced an agreement to acquire innovative...

Company Drug

Huadong Medicine Ends Collaboration on vTv’s TTP273 for Diabetes Treatment

Fineline Cube Jan 2, 2024

US-based vTv Therapeutics LLC has received a cancellation notice from China’s Huadong Medicine Co., Ltd.,...

Company Deals

Roche Secures Diagnostics Deal with LumiraDx for $295M

Fineline Cube Jan 2, 2024

Switzerland’s pharmaceutical giant Roche (SWX: ROG) has sealed a deal to acquire innovative diagnostics technology...

Company Deals

Huadong Medicine Cancels Collaboration with vTv Therapeutics on TTP273 for Type 2 Diabetes Drug

Fineline Cube Jan 2, 2024

vTv Therapeutics LLC, a US-based pharmaceutical company, has announced receiving a cancellation notification from China-based...

Company Drug

Jiangsu Recbio’s REC610 Shingles Vaccine Shows Positive Results in First-In-Human Study

Fineline Cube Jan 2, 2024

Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a Chinese biotechnology company, has announced positive results...

Company Drug

Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity Treatment

Fineline Cube Jan 2, 2024

Innovent Biologics Inc., a biopharmaceutical company based in China (HKG: 1801), has announced the first...

Company Drug

Hainan Poly Pharm’s Novel Nanomedicine PLAT001 Gets US FDA Approval for Clinical Trials

Fineline Cube Jan 2, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...

Company Deals

CareRay Digital Medical Technology to Acquire 30% Stake in UK’s ISDI for USD 15.2 Million

Fineline Cube Jan 2, 2024

CareRay Digital Medical Technology Co., Ltd, a company based in Suzhou (SHA: 688607), has announced...

Company Deals

Jiangsu Hengrui’s SHR-A2009 Earns Fast-Track Status for Metastatic NSCLC Treatment

Fineline Cube Jan 2, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that its in-house developed antibody-drug conjugate...

Company Deals

Grifols Sells 20% Stake in Shanghai RAAS to Haier Group for USD 1.8 Billion

Fineline Cube Jan 2, 2024

Grifols (BME: GRF; NASDAQ: GRFS), a Spanish pharmaceutical company, has announced the formation of an...

Company Deals

MicroPort CardioFlow Medtech to Acquire Controlling Stake in La Ronda for USD 20 Million

Fineline Cube Jan 2, 2024

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...

Company Medical Device

P-Cure Initiates Construction of Affordable Proton Therapy Center in China’s Shandong Province

Fineline Cube Jan 2, 2024

P-Cure, an Israeli company specializing in proton therapy, has commenced construction on a proton therapy...

Company Deals

Medilink Therapeutics Secures Multi-Billion Dollar Deal with Roche for c-MET Targeting ADC

Fineline Cube Jan 2, 2024

Medilink Therapeutics, a Suzhou-based biopharmaceutical company, has entered into a global collaboration and licensing agreement...

Company Deals

Beijing Avistone Pharmaceuticals Raises RMB 1 Billion in Series B Funding to Accelerate Drug Development

Fineline Cube Dec 29, 2023

Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd, based in China, has successfully closed its Series B...

Posts pagination

1 … 422 423 424 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.